# Enzyme By Design

Source: https://onco.cc/companies/enzyme-by-design/  
OnCo record `enzyme-by-design` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Enzyme By Design is engineering a safer version of asparaginase, an enzyme medicine used against childhood acute lymphoblastic leukaemia, to remove a second activity linked to side effects. It is in laboratory testing.

## Summary

Enzyme By Design uses structure-based enzyme engineering to make cancer therapeutics safer, beginning with L-asparaginases, which it engineers to remove the side activity linked to toxicity. Its stated targets are haematological cancers, with possible use in some solid tumours. The NIH RePORTER abstract describes human-like asparaginases with reduced immunogenicity, no L-glutaminase activity and long persistence. In fiscal year 2026 NCI awarded it USD 400,000 under SBIR award 1R43CA306391-01A1.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Enzyme By Design, Inc.; ENZYME BY DESIGN, INC.
- HQ: Chicago, IL
- Type: biotech
- Website: https://www.enzymebydesign.com/

## Notes

- No named product on the company website. Read on enzymebydesign.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://www.enzymebydesign.com/
- NIH RePORTER: SBIR award 1R43CA306391-01A1: https://reporter.nih.gov/project-details/11405207

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- technologies: [Metabolic therapy: starving the tumour of a nutrient](https://onco.cc/technologies/metabolic-therapy/)

---
JSON: https://onco.cc/api/v1/entities/enzyme-by-design.json